Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

Law firm Lowey Dannenberg is investigating Capricor Therapeutics for potential federal securities violations following disclosure that FDA briefing materials relied on an outdated statistical analysis plan for its Deramiocel therapy BLA. The stock fell 64% after the disclosure, and an FDA Advisory Committee subsequently voted against the drug's effectiveness for cardiomyopathy in DMD patients.